Your browser doesn't support javascript.
loading
Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.
Rädler, Patrick D; Wehde, Barbara L; Triplett, Aleata A; Shrestha, Hridaya; Shepherd, Jonathan H; Pfefferle, Adam D; Rui, Hallgeir; Cardiff, Robert D; Perou, Charles M; Wagner, Kay-Uwe.
Afiliação
  • Rädler PD; Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
  • Wehde BL; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
  • Triplett AA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
  • Shrestha H; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
  • Shepherd JH; Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
  • Pfefferle AD; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Rui H; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Cardiff RD; Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Perou CM; Center of Comparative Medicine, University of California, Davis, CA, USA.
  • Wagner KU; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nat Commun ; 12(1): 3742, 2021 06 18.
Article em En | MEDLINE | ID: mdl-34145248
Claudin-low breast cancer represents an aggressive molecular subtype that is comprised of mostly triple-negative mammary tumor cells that possess stem cell-like and mesenchymal features. Little is known about the cellular origin and oncogenic drivers that promote claudin-low breast cancer. In this study, we show that persistent oncogenic RAS signaling causes highly metastatic triple-negative mammary tumors in mice. More importantly, the activation of endogenous mutant KRAS and expression of exogenous KRAS specifically in luminal epithelial cells in a continuous and differentiation stage-independent manner induces preneoplastic lesions that evolve into basal-like and claudin-low mammary cancers. Further investigations demonstrate that the continuous signaling of oncogenic RAS, as well as regulators of EMT, play a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Mamárias Animais / Proteínas Proto-Oncogênicas p21(ras) / Claudinas / Células-Tronco Mesenquimais / Glândulas Mamárias Animais Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Mamárias Animais / Proteínas Proto-Oncogênicas p21(ras) / Claudinas / Células-Tronco Mesenquimais / Glândulas Mamárias Animais Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article